Digitalist Group’s registration document and securities

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
44
Digitalist Group’s registration document and securities note approved

Digitalist Group Plc          Stock Exchange Release           5 July 2018 at 3:30 p.m.

Not to be published or distributed in or into the United States, Canada, Australia, Hong Kong, South Africa or Japan.

On 5 July 2018, the Finnish Financial Supervisory Authority approved Digitalist Group Plc’s (”Digitalist Group” or ”Company”) registration document (”Registration Document”) and securities note (”Securities Note” and, together with the Registration Document, "Prospectus") related to the Company's directed share issues (”Rights Issues”) announced on 31 May 2018 and 20 June 2018 pursuant to the Finnish Securities Market Act. The Registration Document contains information on the Company and its business and financial position. The Registration Document is valid for 12 months after its approval. The Securities Note contains information on the Rights Issues and a summary of the information contained in the Registration Document and the Securities Note.

For its entire period of validity, the Prospectus will be available in Finnish as an electronic version approximately as of 5 July 2018 on the Company’s website at the address https://investor.digitalistgroup.com/fi/inves...are-issues. Upon request, a free hard copy of the Prospectus can be obtained by ordering it by email from the address communications@digitalistgroup.com or by mail to the address Digitalist Group Plc, P.O. Box 486, 00101 Helsinki. The Prospectus is only available in the Finnish language.

DIGITALIST GROUP PLC

Board of Directors

For more information, please contact:

Digitalist Group Plc

CEO Ville Tolvanen, tel. +358 50 3100 642, ville.tolvanen@digitalistgroup.com

DISCLAIMER

The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy, fairness or completeness. The information in this announcement may be subject to change. This announcement is not a prospectus for the purposes of Directive 2003/71/EC (such directive, as amended, together with any applicable implementing measures in the relevant member state of the European Economic Area under such Directive, the “Prospectus Directive”).

The information contained herein is not for publication or distribution, directly or indirectly, in or into the United States, Canada, Australia, Hong Kong, South Africa or Japan. These written materials do not constitute an offer of securities for sale in the United States, nor may the securities be offered or sold in the United States absent registration or an exemption from registration as provided in the U.S. Securities Act of 1933, as amended, and the rules and regulations thereunder. The Company does not intend to register any portion of the offering in the United States or to conduct a public offering of securities in the United States.

The issue, exercise and/or sale of securities in the offering are subject to specific legal or regulatory restrictions in certain jurisdictions. Digitalist Group Plc (“Company”) assumes no responsibility in the event there is a violation by any person of such restrictions.

The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction. Investors must neither accept any offer for, nor acquire, any securities to which this document refers, unless they do so on the basis of the information contained in the applicable prospectus published or offering circular distributed by the Company.

This communication is directed only at (i) persons who are outside the United Kingdom or (ii) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) and (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as “relevant persons”). Any investment activity to which this communication relates will only be available to and will only be engaged with relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

None of the Company and its respective affiliates, directors, officers, employees, advisers or agents accepts any responsibility or liability whatsoever for, or makes any representation or warranty, express or implied, as to the truth, accuracy or completeness of the information in this announcement (or whether any information has been omitted from the announcement) or any other information relating to the Company, its subsidiaries or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this announcement or its contents or otherwise arising in connection therewith.

Attachment

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 4

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Protecting Teeth: Insights from Endodontist Dr. Joubert

Updated Category News Views 7

Preserving Our Natural Chompers Digging into the details of endodontic care, you realize how it's the unsung hero in the dental world. And let's face it, teeth don't get happier on their own when there's a problem on the inside. Dr. Christopher Joubert, a wiz on the endodontic front, spills the beans over at HelloNation about how essential these practices are in keeping...

Continue Reading
Larry Ellison's Moves Signal Confidence in Oracle's Future

Updated Category News Views 7

Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...

Continue Reading
Damp or Dry: The Battle for Healthy Air in Colorado

Updated Category News Views 5

The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 4

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Ajman Spotlights Tourism at Arabian Travel Market 2026

Updated Category News Views 3

Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...

Continue Reading
OneOdio Showcases Innovation at IFA 2026 in Berlin

Updated Category News Views 5

Echoes from Berlin IFA 2026 in Berlin was a cacophony of innovation, as OneOdio wrapped up its showcase with a bang. Boasting interactive activities and live DJ sets, the event echoed OneOdio's drive to meld advanced audio technology with the pulsating needs of music pros and everyday listeners. You couldn’t miss the excitement in the air at Booth 217. Tech Unplugged:...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 4

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 1

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 4

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading

Top 5 Most Recently Viewed Articles

Farmland Partners Reports Third Quarter Growth and Dividends

Updated Category News Views 88

Strong Q3 Performance by Farmland Partners Farmland Partners (NYSE: FPI) has recently reported its impressive third-quarter earnings, highlighting a solid operational performance along with notable asset sales. CEO Luca Fabbri expressed confidence in the company's financial strategies, particularly in debt reduction and shareholder value return, including a special...

Continue Reading
Innovations in Nanotechnology Drug Delivery Transforming Healthcare

Updated Category News Views 317

Future Insights into the Nanotechnology Drug Delivery Market The global Nanotechnology Drug Delivery market is set for an impressive transition, with recent reports highlighting its growth from USD 95.7 billion in 2023 to a staggering USD 213.2 billion by 2032. This ambitious forecast is attributed to a robust CAGR of 9.3% during the period from 2024 to 2032. The driving...

Continue Reading
Loomis Integrates Peregrine Connect for Enhanced Efficiency

Updated Category News Views 152

Loomis Selects Low-Code Solution for Operational Excellence Loomis has made a significant decision to implement Peregrine Connect's no/low-code integration platform, a move aimed at enhancing operational efficiency and regulating costs across its extensive network. As one of the worldwide leaders in payment management systems, Loomis operates in numerous regions,...

Continue Reading
Sngular Names Chris Brown as U.S. Managing Director for Growth

Updated Category News Views 138

Sngular Names Chris Brown as U.S. Managing Director Veteran advanced technology executive Chris Brown has officially joined Sngular as the Managing Director for the United States. His mission is to spearhead U.S.-based growth and client execution strategies through a flexible delivery model that merges onshore leadership with near-shore and global teams. Chris Brown's...

Continue Reading
Sherwin-Williams Faces Challenges After Lowering Earnings Outlook

Updated Category News Views 125

Sherwin-Williams Adjusts Earnings Projections Following Q2 Results The Sherwin-Williams Company (NYSE: SHW) recently faced some challenges after reporting lower-than-expected second-quarter earnings. With adjusted earnings per share (EPS) of $3.38, the results fell short of Wall Street's predictions, which had estimated $3.81 per share. The company's quarterly revenue,...

Continue Reading